All In MedTech

Device Trial Radar · NCT06144632

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF

Safety and Effectiveness Evaluation of the THERMOCOOL SMARTTOUCH SF Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation (PAF)

Last checked: Nov 20, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

237

Actual

Start

Dec 7, 2023

Primary completion

Oct 30, 2025

Study completion Oct 30, 2025

Sponsor

Lead sponsor
Biosense Webster, Inc.Public (JNJ)
Sponsor type
Industry
First posted
Nov 22, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround flow \[STSF\] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF), an irregular heart rate that causing abnormal blood flow.

Conditions

  • Drug Refractory Paroxysmal Atrial Fibrillation

Interventions

  • THERMOCOOL STSF Bi- Directional Navigation CatheterDevice

    THERMOCOOL STSF will be used in conjunction with TRUPULSE Generator to give pulsed field (PF) ablation or radiofrequency (RF) ablation.

  • TRUPULSE GeneratorDevice

    TRUPULSE Generator will be used to deliver PF/RF ablation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Primary Adverse Events (PAEs)Time frame: 7 days post-procedure
  2. Percentage of Participants with Freedom from Documented (Symptomatic and Asymptomatic) Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atrial Flutter (AFL) Episodes and Other Failure ModesTime frame: Up to 274 days

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Grandview Medical Center

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Keck School of Medicine of USC

    Los Angeles, California

26 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.